Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
2-(3,5-bis(trifluoromethyl)phenyl)-N-methyl-2-(methyl-d3)-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide-3,3,3-d3
Application Notes
Useful research chemical for a range of applications
Hazard Compound
No -Refer MSDS for accurate information
Netupitant-d6 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Netupitant-d6 usage and description
Netupitant D6 is a deuterated form of netupitant, a highly potent and selective neurokinin-1 receptor antagonist used in the prevention of chemotherapy-induced nausea and vomiting. It is a white to off-white powder with a molecular weight of 438.5 g/mol and a chemical formula of C23H21D6F3N4O.
Netupitant D6 works by blocking the binding of substance P to the neurokinin-1 receptors in the brain, which prevents the activation of the vomiting reflex pathway. It has a long duration of action, with a half-life of approximately 90 hours, and is administered orally in combination with palonosetron, a 5-HT3 receptor antagonist.
In clinical studies, netupitant D6 has demonstrated superior efficacy in preventing acute and delayed nausea and vomiting compared to standard therapies. It has also been shown to be well-tolerated, with minimal side effects such as constipation, headache, and fatigue.
As with any medication, netupitant D6 should only be used under the guidance of a healthcare professional. It is contraindicated in patients with severe hepatic impairment and may interact with other medications, including those metabolized by CYP3A4.
Overall, netupitant D6 represents a significant advancement in the management of chemotherapy-induced nausea and vomiting, providing patients with a safe and effective option for reducing the debilitating side effects of cancer treatment.
